Opioids in the management of breathlessness in advanced heart failure

Completed

• Conditions: Chronic heart failure; Circulatory System; Chronic Heart Failure

• Registration Number: ISRCTN85268059
• Lead Sponsor: Hull and East Yorkshire Hospitals NHS Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-09-04
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 48

Inclusion Criteria

1. New York Heart Association (NYHA) grade three to four chronic heart failure with systolic dysfunction on echocardiography
2. Receiving optimal medical management (diuretics and Angiotensin Converting Enzymes [ACE] inhibitors/angiotensin 2 antagonists) stable for the past month
3. Aged 18 years and over

Exclusion Criteria

1. Inadequate renal function (Glomerular Filtration Rate [GFR] less than 30 ml/min on Cockroft/Gault formula)
2. Morphine allergy
3. Currently receiving opioid therapy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of breathlessness as measured by the Borg validated score for breathlessness and 11 point Numerical Rating Scale (worst, average and current readings), measured daily whilst taking the trial medications.

Secondary Outcome Measures

Name	Time	Method
1. Distress from breathlessness, measured on days one and four for each trial medication (the first and last days participants take it)<br>2. Satisfaction and coping, measured daily whilst taking the trial medications<br>3. Breathlessness descriptors, measured on days one and four for each trial medication (the first and last days participants take it)<br>4. Adverse effect scores, measured daily whilst taking the trial medications<br>5. Quality of life, measured on days one and four for each trial medication (the first and last days participants take it)